Cardiol Therapeutics Inc - Ordinary Shares - Class A
CRDL
Get informed when a big investor buys or sells
+ FollowMarket Cap$205.18M
Close$
$0.17
85.1% downside
Current Fair Value
85.1% downsideOvervalued by 85.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $205.18 Million |
|---|---|
| Enterprise Value | $179.20 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.39 |
| Beta | 0.52 |
| Outstanding Shares | 114,935,371 |
Return
| Return on Equity | -152.53% |
|---|---|
| Return on Assets | -124.84% |
| Return on Invested Capital | -152.07% |
Valuation & Multiples
| P/E Ratio | -5.17 |
|---|---|
| PEG | -149.89 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -4.89 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$-0.09
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$-0.06
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | 58,600▼ 52.12% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 25.68%▲ 0.10% |
|---|---|
| Total Invested | $31.29M▼ 16.77% |
| Investors Holding | 55▲ 6.00% |
ESG Score
No data
About Cardiol Therapeutics Inc
18 employees
CEO: David G. Elsley Cardiol Therapeutics Inc. operates as a clinical-stage life sciences company, primarily engaged in the discovery and advancement of treatments designed to combat fibrosis and inflammation within the context of cardiovascular diseases. It...